Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

and in those undergoing major orthopedic surgery, treatment and secondary prevention of VTE, and acute coronary syndromes (ACS).

About Atrial Fibrillation

Atrial fibrillation (AF) is a major cause of hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern due to an aging population. In atrial fibrillation, some blood inside the atria may stagnate, and clots may form. If a piece of the clot breaks off and subsequently blocks an artery in the brain, a stroke results. According to the joint ACC/AHA/ESC guidelines for the management of atrial fibrillation, patients with atrial fibrillation have a two- to seven-fold increased risk of stroke and also have an increased risk of death and cardiovascular complications, including myocardial infarction.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development, addressing the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... foam of atom-thick sheets can be made to any ... Rice University. , In microscopic images, the foam ... and walls that reinforce each other. The structure consists ... of graphene oxide that self-assemble with the assistance of ... the foam could find use in structural components, as ...
(Date:7/29/2014)... -- According to the new research report  ... Analysis Software), Delivery Modes (Web Based/Cloud Based) & Whole ... 2018", published by MarketsandMarkets, analyzes and studies the major ... North America , Europe ... of the World (RoW). Browse 78 market ...
(Date:7/29/2014)... July 29, 2014  ImmunoClin Corporation (IMCL) is ... treatment of infectious diseases as well as nutraceuticals. ... prevention of pathologies like cardiovascular disease, Alzheimer,s disease ... ImmunoClin Corporation will complete the strategic relocation of ... , a key center of North American ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
Breaking Biology Technology:Tough foam from tiny sheets 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... Toronto, Ontario - Cedara Software , a ... of medical software technologies, has released a new version ... toolkit, MergeCOM-3. , ,The product is a software development ... and supports flexible DICOM connectivity for software applications. , ...
... into the third year of their Sarbanes-Oxley ... is a good time to pause and reflect on ... on good internal control practices, I hear from hundreds ... how painful implementing 404 has become for their companies. ...
... officials may not be saying it, but they are frightened ... deadly avian flu virus begins quietly in scattered areas of ... on it - with substantial harm done to public health ... one that is exacerbated by the lack of an electronic ...
Cached Biology Technology:The Big Picture of SOX 404 2The Big Picture of SOX 404 3The Big Picture of SOX 404 4UW compound counters Avian flu 2UW compound counters Avian flu 3
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Big data confirms climate extremes are here to stay 2
... dayand starting this week, they will be part of a multinational ... mines left over from as long ago as the First and ... naval exercises in the Baltic Sea this year, where more than ... all part of a day,s work for U.S. Navy divers, who ...
... in air pollution were associated with changes in biomarkers of ... as measures of cardiovascular physiology in healthy young persons, according ... JAMA, a theme issue on Global Health. ... but the mechanisms by which air pollution leads to CVD ...
... A review of studies reporting estimates of the ... malaria over the past 20 years suggests that a ... women attending antenatal (before birth) facilities in sub-Saharan Africa, ... published in the May 16 issue of JAMA ...
Cached Biology News:Undersea warriors, undersea medicine: The future force 2Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 2Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 3Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 4Considerable prevalence of both malaria, STIs exist among pregnant women in sub-Saharan Africa 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
... The Human Neural Stem Cell Functional ... supplements, which can be used for ... of NSCs and the induction of ... lineages. An antibody panel consisting of ...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
Biology Products: